T. McCloskey

Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration.

D. Alberts, D. Roe, Y. Peng, 1988, Cancer research.

Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer.

D. Alberts, C. Taylor, D. Roe, 1992, Journal of the National Cancer Institute.

Clinical pharmacology of a novel diarylsulfonylurea anticancer agent.

M. Holdsworth, Y. Peng, W. Satterlee, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma.

D. Alberts, J. Sosman, P. Stiff, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hepatic drug clearance of three model compounds in normal subjects and cancer patients

T. McCloskey, 1991 .

VerapumiI Reversal of Doxorubicin Resistance in Multidrug-resistant Human Myeloma Cells and Association with Drug Accumulation and DNA Damage1

D. Alberts, W. Dalton, R. Dorr, 2006 .

Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage.

D. Alberts, W. Dalton, R. Dorr, 1988, Cancer research.

High levels of doxorubicin in the tissues of a patient experiencing extravasation during a 4‐day infusion

R. Dorr, M. Dordal, L. M. Koenig, 1989, Cancer.